We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Speaker: Dr. Lluís Montoliu (CNB-CSIC).
Lluis Montoliu is a CSIC Research Scientist at the National Centre for Biotechnology and at the Spanish Research Initiative on Rare Diseases, in Madrid, Spain after working in Heidelberg and Barcelona. He is the Director of the Spanish node of the European Mouse Mutant Archive (EMMA/INFRAFRONTIER). At the CNB, since 1997, he leads a research team interested in basic science (genome organization), and in applied biomedical science, using animal models for the study of human rare diseases, such as albinism. He has pioneered the in vivo use of genome-editing CRISPR approaches in Spain. He is the current President of two scientific societies ESPCR and ARRIGE and serves at the boards of additional national and international associations. He is the President of the CSIC Ethics Committee and serves at the Ethics Panel of ERC. Besides research, he is also interested in ethics, education and popular science.Laboratory has generated numerous animal models of human rare diseases, such as albinism, through standard genetic modifications or using CRISPR-Cas9 genome editing tools, whose use in mice he pioneered in Spain. He is the President of the CSIC Ethics Committee and a member of the Ethics Panel at the ERC in Brussels.
Genome editing is firmly progressing to the clinic, with an increasing number of clinical trials following numerous preclinical experiments where a variety of CRISPR-related tools have been assessed. Innovation is also arriving at the level of delivery systems, with the use of nanotechnology, thanks to the great success obtained with the lipid nanoparticles that were used to encapsulate the mRNA encoding the S protein of the coronavirus. This webinar will review where do we stand today in genome editing, aims achieved and remaining challenges.
Host: Dr. Josep Quer Sivila, Main researcher, Liver Diseases, Vall Hebron Institut de Recerca VHIR
Registre Online: https://gencat.zoom.us/webinar/register/WN_zRJXco6JSdqP2ji_Y4DwGg
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.